Asset profile
onasemnogene abeparvovec · Novartis (NVS)
- Indication
- 5q spinal muscular atrophy (SMA) with bi-allelic SMN1 mutation in patients two years and older, teens and adults
- Also known as
- Itvisma, Itvisma®
Company
NVSNovartis
NVSNovartisNovartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The compan…
On the calendar
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT03505099 | Phase 3 | Completed | Jun 15, 2021 | 30 | 11 of 16 sites in the United States |
| NCT03837184 | Phase 3 | Completed | Jun 29, 2021 | 2 | 0 of 4 sites in the United States |
| NCT03306277 | Phase 3 | Completed | Nov 12, 2019 | 22 | 16 of 16 sites in the United States |
| NCT04042025 | Phase 3 | Active, not recruiting | Dec 31, 2035 | 85 | 18 of 31 sites in the United States |
| NCT03461289 | Phase 3 | Completed | Sep 11, 2020 | 33 | 0 of 10 sites in the United States |
| NCT05335876 | Phase 3 | Active, not recruiting | Apr 29, 2031 | 20 | 1 of 32 sites in the United States |
More from Novartis
Other drugs and candidates from the same company tracked in this sector.
iptacopanprimary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progressionLTP001pulmonary arterial hypertension (PAH)lutetium Lu 177 vipivotide tetraxetanPSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)pelacarsenelevated Lp(a) and established cardiovascular diseaseremibrutinibrelapsing multiple sclerosisvotoplamHuntington's disease